ʻO Trazhenta (inoa inoa Trajenta) kahi papa hou o nā lāʻau lapaʻau antidiabetic. Ua hoʻohana nui ʻia ka poʻe DPP-4 me kahi māka waha o ka hoʻokele e mālama i ka maʻi maʻamau o ka lā 2; ua hōʻiliʻili ʻia kahi hōʻike nui no ka hana pono.
ʻO ka hana ikaika o ka lāʻau lapaʻau ʻo linagliptin. Hoʻohana nui ʻia no kāna mau pono pono o ka maʻi maʻi me nā pathologies kidney, no ka mea ʻaʻole i lawe ʻia ka lāʻau nui ma luna o lākou.
Trazhenta - keʻano a me ka palapala hoʻohālikelike
Hoʻopau, hana hoʻomoʻi ʻo BOEHRINGER INGELHEIM PHARMA (Kelemānia) a ʻo BOEHRINGER INGELHEIM ROXANE (USA) i ka lāʻau lapaʻau ma ke ʻano o nā convex round red tablets. Kuhi ʻia ka hōʻailona o ka mea hana i ka lāʻau mai ka fakes i ka ʻaoʻao hoʻokahi, a kahakaha ʻia ka hōʻailona ʻo "D5" ma kekahi.
Loaʻa kēlā me kēia me 5 mg o ka linagliptin hoʻolaʻa ikaika a me nā ʻano kaulike like ʻole e like me ke starch, dye, hypromellose, magnesium stearate, copovidone, macrogol.
ʻO kēlā me kēia alumini blister pākuhi a 7 a he 10 mau papa o ka lāʻau Trazhenta, ke kiʻi hiki ke ʻike ʻia i kēia ʻāpana. I loko o ka pahu e hiki ai iā lākou ke helu ʻē aʻe - mai ʻelua a ʻewalu papa. Inā he 10 mau papa me nā papa i loko o kahi pōpō, a laila e loaʻa ka 3 mau papa i ka pahu.
Lapaʻau
ʻIke maoli ʻia nā ala o ka lāʻau lapaʻau ma muli o ka kaomi ʻana o ka hana a dipeptidyl peptidase (DPP-4). Hoʻopilikia kēia enzyme
ma luna o nā hormones HIP a me GLP-1, he kuleana koʻikoʻi ka mālama i ka kaulike o ka glucose. Hoʻonui ka mea hoʻonui i ka hana insulin, kōkua i ke kāohi glycemia, a pale i nā mea huna o glucagon. He manawa pōkole kā lākou hana; ma hope iho, ua hoʻopau ʻo HIP a me GLP-1 i nā enzyme. Hoʻopili hou ʻia ʻo Trazhenta me DPP-4, ʻae kēia iā ʻoe e mālama i ke olakino o incretins a hoʻonui i ko lākou pae kūpono.
Hoʻolima ka ʻano o ka mana o Trazhenty i nā kūmole o ka hana o nā mea hoʻohālikelike - Januvius, Galvus, Ongliza. Hoʻohana ʻia ka HIP a me GLP-1 i ka wā i komo ai nā mea kanu i ke kino. ʻAʻole pili me ka maikaʻi o ka lāʻau lapaʻau me ka hoʻoulu ʻana o kā lākou hana, hoʻonui wale ʻia ka lāʻau i ka lōʻihi o ko lākou kūkā ʻana. Ma muli o kēia mau ʻano, ʻo Trazhenta, e like me ka incretinomimetics ʻē aʻe, ʻaʻole ia i hoʻonāukiuki i ka hoʻomohala ʻana o ka hypoglycemia a he hopena maikaʻi kēia no nā papa ʻē aʻe o ka lāʻau hypoglycemic.
Inā ʻaʻole nui paha ka nui o ke kōpiko, kōkua nā incretins e hoʻonui i ka hana o ka insulin endogenous e nā β-cells. ʻO ka hormon GLP-1, he mau helu koʻikoʻi ia o nā mea hiki ke hoʻohālikelike i ka GUI, poloka i ka hoʻopili ʻana o ka glucagon i nā pona o ka ate. Ke kōkua nei kēia mau hana āpau i ka mālama pono i ka glycemia ma ka pae kūpono - e hōʻemi ai i ka hemoglobin glycosylated, ka wikiwiki i ke kō a me ka hoʻokaʻa glucose ma hope o ka hana ʻana i ka manawa o ʻelua mau hola. Ma ka lāʻau paʻakikī me ka hoʻomākaukau me metformin a me ka hoʻomākaukau ʻana no ka olelonlurea, hoʻomaikaʻi ʻia nā hiʻohiʻona glycemic me ka loaʻa ʻole o ka waiwai koʻikoʻi.
Lapaʻau lāʻau
Ma hope o ke komo ʻana i ka hāwele hana ʻana, e hopu koke ka lāʻau iā Cmax ma hope o hoʻokahi hola a me ka hapa. Ke emi nei ka neʻe ʻana i nā lua ʻelua.
ʻO ka hoʻohana ʻana o nā papa me ka meaʻai a i ʻole ka mahele ma ka pharmacokinetics o ka lāʻau ʻaʻole i hoʻopilikia. ʻO ka bioavailability o ka lāʻau hiki ke 30%. Ka pālahalaha haʻahaʻa helu liʻiliʻi, 5% excreted e nā keiki, 85% hoʻopiʻi ʻia me nā feces. ʻAʻole koi kahi ʻano o ke ana o ka pūpū i ka hoʻoneʻe ʻana i ka lāʻau lapaʻau a i ʻole ka loli o ka palena. ʻAʻole i aʻo ʻia nā hiʻohiʻona o nā pharmacokinetics i ke kamaliʻi.
ʻO wai ka lāʻau lapaʻau no
Ua kuhikuhi ʻia ʻo Trazent ma ke ʻano o ka lāʻau lapaʻau mua a i ʻole me ka hoʻohui ʻana me nā lāʻau lapaʻau haʻahaʻa.
- Monotherapy. Inā ʻaʻole ʻae ka mea maʻi hakahaka i nā lāʻau lapaʻau o ka papa o nā bigudins e like me ka metformin (no ka laʻana, me nā ala lāʻau renal a ʻole intolerance pilikino i kāna mau ʻāpana), a me ka loli o ke ola ʻana, ʻaʻole ia e lawe i nā hopena i makemake ʻia.
- ʻElua papa ʻāpana. Hoʻonohonoho ʻia ka Trazent me ka hoʻomākaukau ʻana o ka sulfonylurea, metformin, thiazolidinediones. Inā maʻi ka maʻa i ka insulin, e hoʻohui paha i ka incretinomimetic.
- Nā koho ʻekolu-wae. Inā ʻaʻole maikaʻi loa nā algorithm algorithm mua, ua hui pū ʻo Trazhenta me ka insulin a me kekahi ʻano lāʻau antidiabetic me kahi ʻano like ʻole o ka hana.
ʻAʻole i hoʻouna ʻia iā Trazhent
Lanakila ʻo Linagliptin no ia mau ʻano o ka maʻi maʻi.
- ʻAno maʻi type 1;
- Ua hoʻonāukiuki ʻia ʻo Ketoacidosis e ka maʻi maʻi;
- ʻLelo a me ka lactating;
- Nā keiki a ʻōpio;
- Hypersensitivity i nā mea o ke ʻano.
Nā hopena hopena
Ma ke ala e lawe ai i ka linagliptin, hiki i nā hopena hopena ke ulu.
- Nasopharyngitis (kahi maʻi o ke ʻano infectious);
- Nā kiʻekiʻe kāwili;
- Hoʻoikaika pū kekahi;
- ʻO ka pancreatitis
- Hoʻonui i ka triglycerol (i ka wā i hui pū me nā huaʻōlelo sulia o ka ʻalekilule)
- Hoʻohui i nā waiwai LDL (me ka hoʻokele o ka pioglitazone);
- ʻO ka ulu kino kino;
- Nā hōʻailona hypoglycemic (e kūʻē i ke ʻano o ka lāʻau ʻelua a me ʻekolu-ʻekolu.
ʻO ke kū pinepine a me ka nui o nā hopena maikaʻi aʻe e hoʻomake ma hope o ka ʻai ʻana iā Trazhenta e like me ka helu o nā hopena ʻaoʻao ma hope o ka hoʻohana ʻana i ka placebo. ʻO ka hapa pinepine, hōʻike ʻia nā hopena i loko o ka triple complex therapy o Trazhenta me nā metformin a me nā derivatives o sulfonylurea.
Hiki i ka lāʻau lapaʻau ke hōʻeha i nā pilikia koikoi, koʻikoʻi kēia e noʻonoʻo inā ke kaʻa ʻana i nā kaʻa a me nā ʻano hana paʻakikī.
Ke keu
Hāʻawi ʻia nā mea komo i nā papa ʻelua 120 (600 mg) i ka manawa. ʻAʻole i hoʻopilikia ʻia kahi overdose hoʻokahi i ke kūlana olakino o nā poʻe hana hana mai kahi hui olakino olakino. I waena o nā maʻi maʻi, ua loaʻa ʻole nā hihia nui loa e nā helu olakino. A eia naʻe, inā ʻaʻole ke kumu a me ka makemake ʻole o ka nui o nā hewa i ka manawa like, pono ka mea a ka mea ʻai e holoi i ka ʻōpū a me nā ʻōpū ma waho e pale i kahi ʻāpana o ka lāʻau lapaʻau, hāʻawi i nā sorbents a me nā lāʻau lapaʻau hou e like me nā hōʻailona, hōʻike i ke kauka.
Pehea e lawe ai i ka lāʻau
Pono e hana e like me nā ʻōlelo i hana no ka hoʻohana ʻana i ʻekolu mau manawa i ka lā, 1 papa (5 mg). Inā hoʻohana ʻia ka lāʻau lapaʻau i ka mālama ʻana i ka paʻakikī me ka metformin, a laila mālama ʻia ka nui o ka hopena.
Diabetes me ka renal a i ʻole hepatic insufficiency e pono ai e hoʻoponopono he hoʻoponopono. ʻAʻole ʻokoʻa nā maʻamau maʻamau no nā poʻe maʻi o nā makahiki pākeke. I kahi senile (mai 80 mau makahiki), ʻaʻole i kuhikuhi ʻia ʻo Trazhent ma muli o ka nele o ke akamai o ka maʻi ma kēia ʻano makahiki.
Inā hala ka manawa no ka lawe ʻana i ka lāʻau lapaʻau, pono ʻoe e inu i kahi ʻapo i ka hiki. ʻAʻole hiki ke hoʻolōʻihi i ke ʻano. ʻAʻole pili ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau i ka manawa ʻai.
ʻO ka mana o ka trazhenti ma ka hāpai ʻana a me ka lactation
ʻAʻole i hoʻopuka ʻia nā hopena o ka hoʻohana ʻana i ka lāʻau e nā wahine hāpai. Ma kēia manawa, ua mālama ʻia nā noiʻi ʻana i nā holoholona wale nō, ʻaʻole i hōʻike ʻia nā hōʻailona o nā palaka o ka reproduction. A ʻo ka wā, i ka wā hāpai ʻana, ʻaʻole i kuhikuhi ʻia nā wāhine i ka lāʻau lapaʻau.
I nā hoʻokolohua me nā holoholona, ʻike ʻia ua hiki i ka lāʻau lapaʻau ke komo i loko o ka waiū o ka makuahine o ka wahine. No laila, i ka wā o ka hānaiʻana i nā wahine, ʻaʻole i kuhikuhi ʻia ʻo Trazhent. Inā makemake ke kūlana o ke olakino i kēlā ʻano maʻi, ua hoʻohuli ʻia ke keiki i ka meaʻai maʻamau.
ʻAʻole i hōʻike ʻia nā hoʻokolohua ma ka hopena o ka lāʻau lapaʻau ma ka hiki ke hānai i kahi keiki. ʻAʻole i hōʻike ʻia nā ʻano hoʻokolohua like me nā holoholona ma kahi o kēia ʻaoʻao.
Hoʻohui nūhou
ʻO ka hoʻohana like ʻana o Trazhenta a me Metformin, ʻoiai inā i ʻoi aku ka nui o ka lāʻau ma mua o ke alapine, ʻaʻole ia i alakaʻi i nāʻokoʻa koʻikoʻi i loko o ka pharmacokinetics o nā lāʻau.
ʻO ka hoʻohana ʻana i ka hoʻohana ʻana o Pioglitazone ʻaʻole e loli i ka pono pharmacokinetic o nā lāʻau ʻelua.
ʻAʻole hōʻeha ka mālama loea me Glibenclamide no Trazhenta, no ka mea hope loa, ua emi iki ʻo Cmax (ma ka 14%).
Hōʻike kekahi hopena like o ka hoʻopili ʻana e nā lāʻau ʻē aʻe o ka papa sulfonylurea.
ʻO ka hui pū ʻana o ka ritonavir + linagliptin e hoʻonui nei i ka Cmax ma 3 manawa, ʻaʻole pono nā loli like.
ʻO nā hui pū me Rifampicin e hoʻonāukiuki i ka hōʻemi ma Cmax Trazenti. ʻO ka hapa, mālama ʻia nā hiʻohiʻona o ka lāʻau lapaʻau, akā ʻaʻole e hana ka lāʻau lapaʻau i ka 100%.
He mea weliweli e kuhikuhi iā Digoxin i ka manawa like me ka lynagliptin: ʻaʻole loli nā pharmacokinetics o nā lāʻau ʻelua.
ʻAʻole pili ʻo Trazhent i ka hiki iā Varfavin.
Hoʻomaʻamaʻa ʻia nā hoʻololi liʻiliʻi me ka hoʻohana like ʻana o ka linagliptin me ka simvastatin, akā ʻo ka mimetin mimetic ʻaʻole ia e hoʻopilikia nui i kona mau hiʻohiʻona.
E kū'ē i ke ʻano o ka mālama ʻana me Trazhenta, hiki i nā mea kūlohelohe waha ke hoʻohana manuahi ʻole.
Nā ʻōlelo ʻokoʻa
ʻAʻole i kuhikuhi ʻia ʻo Trazent no ka maʻi maʻamau a me ka ketoacidosis, kahi hoʻohui o ka maʻi maʻi.
ʻO ka loli o nā kūlana hypoglycemic ma hope o ka mālama ʻana me ka linagliptin, i hoʻohana ʻia me ka monotherapy, i lawa i ka nui o nā hihia me ka pletebo.
Ua hōʻike ʻia nā hoʻokolohua haukapila i ʻike ʻole ʻia ka lōʻihi o ka piʻi ʻana o ka hypoglycemia i ka wā e hoʻohana ai ʻo Trezhenta i ka hui hoʻohui ʻana i ka mālama ʻana, ʻoiai ʻaʻole hiki i ke ʻano koʻikoʻi ke kumu linagliptin, akā metformin a me nā lāʻau lapaʻau o ka pūʻulu thiazolidinedione.
E nānā pono ka makaʻala ke koho i Trazhenta i ka hui pū me nā lāʻau o ka papa sulfonylurea, no ka mea he kumu lākou no ka hypoglycemia. I ka hopena koʻikoʻi, pono ia e hoʻoponopono i ka nui o nā lāʻau lapaʻau o ka hui sulfonylurea.
ʻAʻole pili ʻo Linagliptin i ka hopena o ka hoʻomohala ʻana i nā ala āpau o ka puʻuwai a me nā kīʻaha koko.
I ka hui hui, hiki ke hoʻohana ʻia ʻo Trazhent a me ke koʻikoʻi paha o ka hana renal impaired.
I ka poʻe maʻi o ka wā pākeke (ma mua o 70 mau makahiki), hōʻike ʻo Trezenta i hōʻike maikaʻi i ka hopena HbA1c: ʻo ka hemoglobin glycosylated mua he 7.8%, ka hopena - 7.2%.
ʻAʻole hoʻonā ka lāʻau lapaʻau i ka piʻi nui o ka pilikia cardiovascular. ʻO ka pahuhopu mua e hōʻike ana i ka neʻe a me ka manawa o ka make, hōʻeha ka naʻau, ka puʻuwai, ka hoʻomau ʻole o ka angina pectoris e koi ana i ka hoʻokipa, maʻi ma waena o nā poʻe maʻi maʻi i lawe i ka linagliptin a ʻoi aku ka hopena a ma hope o nā mea hana ma ka hui mana i loaʻa ka placebo a i nā hoʻohālikelike i nā lāʻau lapaʻau.
I kekahi mau hihia, ua hoʻāla ʻia ka hoʻohana ʻana o ka linagliptin i ka hōʻeha ʻana i ka maʻi pancreatitis.
Inā loaʻa nā hōʻailona (ʻeha hōʻeha i ka epigastrium, dyspepsia, nāwaliwali ākea), pono e hoʻōla i ka lāʻau lapaʻau a nīnau aku i kāu kauka.
ʻAʻole i hoʻokele ʻia nā haʻawina e pili ana i ka mana o Trazhenta i ka hiki ke hoʻokele i nā kaʻa a me nā ʻākana paʻakikī, akā no ka hiki ʻana ke hoʻopohapula hiki, e lawe i ka lāʻau lapaʻau inā pono, me ka hopohopo kiʻekiʻe a me ke ʻano wikiwiki.
Nā hōʻike a me ke kumu kūʻai o ka lāʻau lapaʻau
No ka lāʻau lapaʻau Trazhenta, aneʻi ke kumukūʻai mai 1500-1800 rubles no nā papa 30 no ka nui o ka nui o 5 mg. Hoʻokuʻu ʻia ka lāʻau lapaʻau kāpena.
ʻO nā hui o ka papa inoa o ka papa DPP-4 e pili ana iā Januvia e pili ana i ka synagliptin, Onglizu e pili ana i ka saxagliptin a me Galvus me ka hāmeʻa vildagliptin. Ke kūpono nei kēia mau lāʻau lapaʻau i ka code 4 o ka ATX.
Hoʻohui ʻia kahi hopena like ʻole e nā lāʻau ʻo Sitagliptin, Alogliptin, Saksagliptin, Vildagliptin.
ʻAʻohe kūlana kūikawā no ka mālama ʻana o Trazenti i nā ʻōlelo kuhikuhi. Noʻokiʻekolu mau makahiki (e like me ka lā pau o ka manawa), mālama ʻia nā papa i ka mahana o ka lumi (a hiki i +25 mau palena) i kahi wahi pōʻeleʻele ʻole i loaʻa e nā keiki. ʻAʻole hiki ke hoʻohana ʻia nā lāʻau lapaʻau hoʻopau, pono e kiola ʻia.
ʻO ka maʻi maʻi a me nā kauka e pili ana iā Trazhent
ʻO ka hana koʻikoʻi o Trazenti i nā hui like ʻole i hōʻoia ʻia e nā haʻawina a me nā hana lapaʻau. Ua makemake nā Endocrinologists e hoʻohana i ka linagliptin e like me ka lāʻau lapaʻau mua a i ʻole ke hui pū ʻana. Me ka uluʻana i ka hypoglycemia (kaumaha nui i ke kino, maikaʻi kaʻai ʻana), ʻaʻole i ka lāʻau lapaʻau o ka sulfonylurea, ua kuhikuhi ʻia i Trazent, aia nā loiloi e pili ana i ka lāʻau o ka lāʻau no ka pale ʻana i ka insulin a me ka momona. Ua loaʻa i nā maʻi maʻi he nui i ka lāʻau ma ke ʻano o ka mālama paʻakikī, no laila he paʻakikī ke loiloi i kona pono, akā i ka laulā, hauʻoli nā poʻe a pau me ka hopena.
Hoʻololi ka poʻe DPP-4, ka mea a Trazhenta, ʻaʻole wale i ka haʻi aku i nā hana antidiabetic, akā, i ka piʻi ʻana o ka palekana, no ka mea ʻaʻole lākou e hoʻonāukiuki i ka hopena hypoglycemic, ʻaʻole i hāʻawi i ka loaʻa kālā, a ʻaʻole i hoʻonui i ka maikaʻi ʻole. I kēia manawa, ua manaʻo ʻia kēia papa o nā lāʻau lapaʻau kekahi o nā mea i hoʻohiki mua ʻia no ka mālama ʻana i ka maʻi type 2.
